Details

Details

Title The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum (ARRAY BioPharma Inc.)

IRB ARRY 162311

CC 13-1209

Hospital Fairview, Hillcrest, Main Campus

Stage Recurrent/Relapsed

Phase Phase 3

Disease Fallopian Tube, Gynecologic, Ovarian, Peritoneal

Description

Description

Trial Description Not Available
Inclusion Criteria

Inclusion Criteria

Inclusion Criteria Not Available
Exclusion Criteria

Exclusion Criteria

Exclusion Criteria Not Available